Dr. Tytteli Turunen is originally from Finland and before joining Schepens Eye Research Institute of Mass. Eye and Ear (Boston, MA) as a Research fellow she received her M.Sc. in Biotechnology from University of Kuopio (Finland), followed by Ph.D. in Molecular Medicine from University of Eastern Finland. In her PhD, she studied gene therapy vectors in preclinical settings and developed gene delivery vectors for gene therapy of familial hypercholesterolemia. Her postdoctoral studies at Schepens Eye Research Institute are focused particularly on VEGF signaling pathways and inhibitors in choroidal and retinal angiogenesis.
Dr. Tytteli Turunen's research interests include Retinal degeneration; Diabetic retinopathy; AMD; VEGF signaling in choroidal and retinal angiogenesis; Glaucoma; Neurotrophic retinal therapies; Gene therapy; Ocular gene therapy; Vascular gene therapy; Cell therapies